Salt Lake City, United States
Pyrexar Medical is a leading innovator in the biotechnology and healthcare industries, specializing in the development and production of advanced hyperthermia treatment systems. These systems, known as PYREXAR Hyperthermia (PYREXAR HT), have been proven to significantly enhance the effectiveness of ionizing radiation in treating solid tumors by up to 3X, while minimizing damage to healthy tissues. The company boasts a strong global presence with established distribution and support networks across the US, Europe, and Asia.
Utilizing non-invasive radio-frequency (RF) energy, PYREXAR systems deliver therapeutic heating, targeting cancerous tumors with precision. The treatments, which have been subject to multi-center clinical trials over the past 30 years, have demonstrated remarkable success in improving survival rates for various malignancies when combined with radiotherapy.
A notable recent development is the integration of PYREXAR technology with 1.5 Tesla MR systems, enabling simultaneous RF heating and MR Imaging. This advancement allows for real-time thermometry and investigation of treatments for deep-seated tumors, generating renewed interest in PYREXAR technology as a valuable adjunct to conventional cancer treatments.
Founded in 2015, Pyrexar Medical operates at the forefront of medical device manufacturing, offering a potential growth opportunity for investors seeking to tap into the expanding biotechnology and healthcare sectors.
